Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Gerald M. Higa"'
Autor:
Gerald M. Higa, Corbin Sypult
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 2016, Iss 10, Pp 27-34 (2016)
Externí odkaz:
https://doaj.org/article/09f7f57777ce4b84ae3c95c9ba4edd17
Autor:
Gerald M. Higa
Publikováno v:
Oncology Reviews, Vol 2, Iss 1, Pp 21-28 (2011)
Numerous clinical trials support the biological relevance of the HER2 oncoprotein in breast cancer. In spite of improved outcomes, overexpression of the receptor is associated with increased risks of disease relapse, even in patients with early, and
Externí odkaz:
https://doaj.org/article/01038606ff3f44e1a7e5fa269f174e30
Autor:
Gerald M. Higa, Ryan G. Fell
Publikováno v:
International Journal of Breast Cancer, Vol 2013 (2013)
Classification of breast cancer as endocrine sensitive, hormone dependent, or estrogen receptor (ER) positive refers singularly to ERα. One of the oldest recognized tumor targets, disruption of ERα-mediated signaling, is believed to be the mechanis
Externí odkaz:
https://doaj.org/article/e688a76f271245858af3adaf90674919
Publikováno v:
Scientifica, Vol 2012 (2012)
Dynamic interactions between microorganism and host have evolved in such a way that while microbial pathogens are the cause of many human infections, a symbiotic relationship is also known to exist. Another important anomaly is that exposure to patho
Externí odkaz:
https://doaj.org/article/36832d17a2c749e7a9461bb9456846bd
Publikováno v:
Journal of Analytical Oncology. 12:29-36
Introduction: Deaths due to colorectal cancer are disproportionately higher than either breast or prostate cancers even though the majority of new cases are potentially curable at diagnoses. If only half of the losses is due to metastatic disease at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f19d0d141be4f63186cebcef57506089
https://doi.org/10.30683/1927-7229.2023.12.05
https://doi.org/10.30683/1927-7229.2023.12.05
Autor:
Janna Baker Rogers, Gerald M Higa
Publikováno v:
Journal of Pain Research. 15:909-924
Pain is among the most debilitating symptoms in patients with cancer. Except for their relatively frequent use during end-of-life care, opioids are often, though not routinely, prescribed during the course of the disease. Whereas the clinical phenome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f0bc9160446ec413dfe72b389e8861c
https://doi.org/10.2147/jpr.s349107
https://doi.org/10.2147/jpr.s349107
Publikováno v:
Breast Cancer : Targets and Therapy
Even though gene amplification or protein overexpression occurs in approximately one-fifth of all breast cancers, the discovery of HER2 has, nevertheless, had profound implications for the disease. Indeed, the characterization of the receptor resulte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf1cdc109e4b0cbc64dd2bfc8c90117a
https://doi.org/10.2147/bctt.s288344
https://doi.org/10.2147/bctt.s288344
Publikováno v:
Gastrointest Tumors
Introduction: In 2020, colorectal cancer will be the fourth most frequently diagnosed malignant neoplasm and the second leading cause of site-specific, cancer-related deaths in the USA. Notably, 80% of the new cases are, by staging criteria, potentia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b5fccbd986755fceb3dfdb347479d31
https://doi.org/10.1159/000513960
https://doi.org/10.1159/000513960
Publikováno v:
Journal of Analytical Oncology. 9:25-32
The improvement in tumor outcomes associated with the use of immune checkpoint inhibitors (ICIs) is supported by results of numerous clinical trials. Even though most publications reporting the clinical efficacy of these agents include a discussion o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6057bd3e6f7611a5bc3f88daa0a9ebbf
https://doi.org/10.30683/1927-7229.2020.09.04
https://doi.org/10.30683/1927-7229.2020.09.04
Publikováno v:
Res Social Adm Pharm
Objective To assess the factors related to potentially inappropriate medication (PIM) use in elderly patients with cancer, as well as to compare the PIM prevalence in older adults with and without cancer. Methods Data from the Surveillance, Epidemiol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eab67b471def7ab9ffde23c3d4b0028
https://doi.org/10.1016/j.sapharm.2019.12.018
https://doi.org/10.1016/j.sapharm.2019.12.018